177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

计划入组 93 人 · 首次发布于 2022 年 8 月 11 日

Terbium 161 PSMA in Lutetium-177 PSMA Naive Patients

计划入组 60 人 · 首次发布于 2026 年 3 月 2 日

Phase I Study of Docetaxel and 177-Lutetium-PSMA-I&T in First-Line Treatment for Patients With Metastatic Castration-Resistant Prostate Adenocarcinoma

计划入组 18 人 · 首次发布于 2026 年 1 月 5 日

Lutetium-177 zadavotide guraxetan

177Lu-PSMA-R2

Lutetium-177-PSMA-I&T

Puma Biotechnology

United States

Lutetium-PSMA Combination Therapies Show Promise in Advanced Prostate Cancer

UpFrontPSMA Trial: Lutetium-PSMA Plus Docetaxel Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer

Precede Bio's Liquid Biopsy Shows Promise in Predicting Response to Lutetium-PSMA Therapy in Prostate Cancer